Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers

Purpose: Epigenetic alterations are common and can now be addressed in a parallel fashion. We investigated the methylation in bladder cancer with respect to location in genome, consistency, variation in metachronous tumors, impact on transcripts, chromosomal location, and usefulness as urinary markers. Experimental Design: A microarray assay was utilized to analyze methylation in 56 samples. Independent validation was conducted in 63 samples by a PCR-based method and bisulfite sequencing. The methylation levels in 174 urine specimens were quantified. Transcript levels were analyzed using expression microarrays and pathways were analyzed using dedicated software. Results: Global methylation patterns were established within and outside CpG islands. We validated methylation of the eight tumor markers genes ZNF154 (P < 0.0001), HOXA9 (P < 0.0001), POU4F2 (P < 0.0001), EOMES (P = 0.0005), ACOT11 (P = 0.0001), PCDHGA12 (P = 0.0001), CA3 (P = 0.0002), and PTGDR (P = 0.0110), the candidate marker of disease progression TBX4 (P < 0.04), and other genes with stage-specific methylation. The methylation of metachronous tumors was stable and targeted to certain pathways. The correlation to expression was not stringent. Chromosome 21 showed most differential methylation (P < 0.0001) and specifically hypomethylation of keratins, which together with keratin-like proteins were epigenetically regulated. In DNA from voided urine, we detected differential methylation of ZNF154 (P < 0.0001), POU4F2 (P < 0.0001), HOXA9 (P < 0.0001), and EOMES (P < 0.0001), achieving 84% sensitivity and 96% specificity. Conclusions: We initiated a detailed mapping of the methylome in metachronous bladder cancer. Novel genes with tumor, chromosome, as well as pathway-specific differential methylation in bladder cancer were identified. The methylated genes were promising cancer markers for early detection of bladder cancer. Clin Cancer Res; 17(17); 5582–92. ©2011 AACR.

[1]  R. Dahiya,et al.  Epigenetic Inactivation of Wnt Inhibitory Factor-1 Plays an Important Role in Bladder Cancer through Aberrant Canonical Wnt/β-Catenin Signaling Pathway , 2006, Clinical Cancer Research.

[2]  S. Brosman,et al.  Bladder tumors. Treated natural history. , 1986, Progress in clinical and biological research.

[3]  L. de Leval,et al.  Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. , 2010, European urology.

[4]  M. Frommer,et al.  CpG islands in vertebrate genomes. , 1987, Journal of molecular biology.

[5]  P. Guldberg,et al.  Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events , 2011, International journal of cancer.

[6]  B. Christensen,et al.  Identification of Methylated Genes Associated with Aggressive Bladder Cancer , 2010, PloS one.

[7]  S. Scherer,et al.  Epigenetic Regulation of HYAL-1 Hyaluronidase Expression , 2008, Journal of Biological Chemistry.

[8]  N. Tommerup,et al.  Isolation and fine mapping of 16 novel human zinc finger-encoding cDNAs identify putative candidate genes for developmental and malignant disorders. , 1995, Genomics.

[9]  J. Fernández-Gómez,et al.  Myopodin methylation is associated with clinical outcome in patients with T1G3 bladder cancer. , 2010, The Journal of urology.

[10]  R. Lothe,et al.  Three Epigenetic Biomarkers, GDF15, TMEFF2, and VIM, Accurately Predict Bladder Cancer from DNA-Based Analyses of Urine Samples , 2010, Clinical Cancer Research.

[11]  M. Esteller,et al.  Identification of PMF1 Methylation in Association with Bladder Cancer Progression , 2008, Clinical Cancer Research.

[12]  Gangning Liang,et al.  Detection of Methylated Apoptosis-Associated Genes in Urine Sediments of Bladder Cancer Patients , 2004, Clinical Cancer Research.

[13]  Wen-Jeng Wu,et al.  Increase sensitivity in detecting superficial, low grade bladder cancer by combination analysis of hypermethylation of E-cadherin, p16, p14, RASSF1A genes in urine. , 2010, Urologic oncology.

[14]  Paul Cairns,et al.  Gene methylation and early detection of genitourinary cancer: the road ahead , 2007, Nature Reviews Cancer.

[15]  N. Seki,et al.  CpG hypermethylation of collagen type I alpha 2 contributes to proliferation and migration activity of human bladder cancer. , 2009, International journal of oncology.

[16]  A. Riggs,et al.  Epigenetic mechanisms of gene regulation , 1996 .

[17]  F. Mostofi,et al.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. , 1998, The American journal of surgical pathology.

[18]  Long-Cheng Li,et al.  MethPrimer: designing primers for methylation PCRs , 2002, Bioinform..

[19]  S. Hirohashi,et al.  Genome‐wide DNA methylation profiles in urothelial carcinomas and urothelia at the precancerous stage , 2010, Cancer science.

[20]  R. Kitazawa,et al.  BAMBI gene is epigenetically silenced in subset of high‐grade bladder cancer , 2009, International journal of cancer.

[21]  S. Chi,et al.  Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. , 2001, Cancer research.

[22]  S. Goodman,et al.  Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. , 2006, Journal of the National Cancer Institute.

[23]  B. Weber,et al.  The Brn-3b POU family transcription factor represses expression of the BRCA-1 anti-oncogene in breast cancer cells , 1999, Oncogene.

[24]  H. Stein,et al.  DNA methylation profiling of transcription factor genes in normal lymphocyte development and lymphomas. , 2007, The international journal of biochemistry & cell biology.

[25]  S. Cross,et al.  Promoter Hypermethylation Identifies Progression Risk in Bladder Cancer , 2007, Clinical Cancer Research.

[26]  M. Esteller,et al.  Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays , 2007, British Journal of Cancer.

[27]  Eun-Jung Kim,et al.  RUNX3 inactivation by point mutations and aberrant DNA methylation in bladder tumors. , 2005, Cancer research.

[28]  Peter A. Jones,et al.  Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma. , 2005, European journal of cancer.

[29]  K. Husgafvel‐Pursiainen,et al.  Promoter Hypermethylation in Tumour Suppressor Genes Shows Association with Stage, Grade and Invasiveness of Bladder Cancer , 2008, Oncology.

[30]  Ioannis Panagopoulos,et al.  Promoter analysis of epigenetically controlled genes in bladder cancer , 2008, Genes, chromosomes & cancer.

[31]  Torben F. Ørntoft,et al.  Identifying distinct classes of bladder carcinoma using microarrays , 2003, Nature Genetics.

[32]  S. Izraeli,et al.  Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. , 2009, Blood.

[33]  Rudolf Jaenisch,et al.  Targeted mutation of the DNA methyltransferase gene results in embryonic lethality , 1992, Cell.

[34]  A. Riggs,et al.  Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay , 2007, Proceedings of the National Academy of Sciences.

[35]  B. Migeon.  Concerning the role of X-inactivation and DNA methylation in fragile X syndrome. , 1992, American journal of medical genetics.

[36]  S. Goodman,et al.  Tissue inhibitor of metalloproteinases-3 promoter methylation is an independent prognostic factor for bladder cancer. , 2008, The Journal of urology.

[37]  S. Baylin,et al.  Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer , 2004, Laboratory Investigation.

[38]  Peter A. Jones,et al.  Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. , 2010, Cancer research.

[39]  C. Cordon-Cardo,et al.  Discovery of myopodin methylation in bladder cancer , 2008, The Journal of pathology.

[40]  Tongyu Zhu,et al.  A Novel Set of DNA Methylation Markers in Urine Sediments for Sensitive/Specific Detection of Bladder Cancer , 2007, Clinical Cancer Research.

[41]  F. Algaba,et al.  Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. , 2000, The Journal of urology.

[42]  Peter A. Jones,et al.  Epigenetics in human disease and prospects for epigenetic therapy , 2004, Nature.

[43]  Lawrence D. True,et al.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder , 1998 .

[44]  Daiya Takai,et al.  Comprehensive analysis of CpG islands in human chromosomes 21 and 22 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[45]  D. Latchman,et al.  Brn-3b enhances the pro-apoptotic effects of p53 but not its induction of cell cycle arrest by cooperating in trans-activation of bax expression , 2006, Nucleic acids research.

[46]  R. Sobti,et al.  Hypermethylation-mediated partial transcriptional silencing of DAP-kinase gene in bladder cancer , 2010, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[47]  S. Culine,et al.  A Lower Risk of Dying from Urological Cancer in Down Syndrome: Clue for Cancer Protecting Genes on Chromosome 21 , 2009, Urologia Internationalis.

[48]  Ishtiaq Rehman,et al.  Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  B. Czerniak,et al.  Aberrant Promoter Methylation of Multiple Genes during Pathogenesis of Bladder Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[50]  Rudolf Jaenisch,et al.  Role for DNA methylation in genomic imprinting , 1993, Nature.